ORIGINAL RESEARCH article
Front. Immunol.
Sec. Viral Immunology
This article is part of the Research TopicThe Influence of SARS-CoV-2 Infection and Long-COVID on The Incidence of Viral CoinfectionView all 15 articles
400 AU/mL IgG Protective Threshold Against SARS-CoV-2 XBB Reinfection in Chinese Inactivated Vaccine Recipients: Implications for Booster Vaccination
Provisionally accepted
Zhiying Yin1*
Mengcheng Yin2,3
Fei Zhao4Canya Fu4Wenjie Xu5Quanjun Fang5Xiaoying Gong5
Shuangqing Wang5
Zheng Canjie5- 1Quzhou Center for Disease Control and Prevention, Quzhou, China
- 2Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, China
- 3Huazhong University of Science and Technology Tongji Medical College, Wuhan, China
- 4Zhejiang Chinese Medical University Department of Epidemiology, Hangzhou, China
- 5Quzhou City Center for Disease Control and Prevention, Quzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Data on antibody dynamics and protective threshold generated by infection with Omicron subvariants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly among populations that have primarily (>90%) received inactivated coronavirus disease 2019 (COVID-19) vaccines, remain limited. Using data from two large-scale paired serosurveys, we analyzed real-world changes in SARS-CoV-2 antibody levels associated with specific hybrid immunity. Methods: The history of COVID-19 vaccination and SARS-CoV-2 infection were recorded for each participant. Serum samples collected at three-month intervals were analyzed for antibody levels against nucleocapsid (N) and spike (S) proteins using chemiluminescent microparticle immunoassay (CMIA). Linear mixed-effects model (LMM) and restricted cubic spline analysis were applied to assess antibody dynamics and determine protection thresholds, respectively. Results: A total of 4,065 participants were recruited in February and May 2023, with 2,894 completing both sampling rounds. Over three months, median IgG antibody levels declined by 28% (from 396.39 to 285.80 AU/mL). Prior infection and vaccination were significantly associated with higher antibody levels, while increasing age correlated with an annual decay of 0.38 AU/mL (most prominent in adults ≥60 years, 32.7% of whom fell below the protective threshold by follow-up). The IgG threshold for protection against XBB reinfection was 400 AU/mL, and each additional vaccination reduced reinfection risk by 13–15%. Conclusion: The 400 AU/mL IgG threshold provides a actionable quantitative guideline for prioritizing booster doses in Chinese adults aged ≥60 years (the fastest antibody decay subgroup) and high-risk groups. Routine antibody testing combined with this threshold could optimize targeted COVID-19 vaccination strategies in inactivated vaccine-predominant populations.
Keywords: Antibody dynamics, hybrid immunity, Inactivated vaccine, Protective threshold, SARS-CoV-2
Received: 16 Dec 2025; Accepted: 02 Feb 2026.
Copyright: © 2026 Yin, Yin, Zhao, Fu, Xu, Fang, Gong, Wang and Canjie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhiying Yin
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.